Search results for "adenovirukset"

showing 2 items of 2 documents

Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months

2016

Up to 80% of the cost of vaccination programmes is due to the cold chain problem (that is, keeping vaccines cold). Inexpensive, biocompatible additives to slow down the degradation of virus particles would address the problem. Here we propose and characterize additives that, already at very low concentrations, improve the storage time of adenovirus type 5. Anionic gold nanoparticles (10−8–10−6 M) or polyethylene glycol (PEG, molecular weight ∼8,000 Da, 10−7–10−4 M) increase the half-life of a green fluorescent protein expressing adenovirus from ∼48 h to 21 days at 37 °C (from 7 to >30 days at room temperature). They replicate the known stabilizing effect of sucrose, but at several orders of…

0301 basic medicineSucroseSucroseTime FactorsvirusesGeneral Physics and AstronomyMetal Nanoparticles02 engineering and technologyvaccinationsvaccine storagePolyethylene Glycolschemistry.chemical_compoundMiceImmunogenicity VaccineDrug StabilityModelsAdenovirus Vaccinesvaccineta318ta317MultidisciplinaryChemistryImmunogenicityadenoviruksetQadenovirus021001 nanoscience & nanotechnologyImmunogenicityOrders of magnitude (mass)Cold Temperaturevaccine; adenovirus; additives; nanoparticlesInfectious DiseasesColloidal goldModels Animaladditives0210 nano-technologyInfectionBiotechnologyHalf-LifeScienceDrug StorageBioengineeringPolyethylene glycolModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyArticleVaccine RelatedExcipients03 medical and health sciencesPEG ratioAnimalsThermal stabilityChromatographyAnimalPreventionRational designta1182General ChemistryBiologicalVirology030104 developmental biologyadenovirusesFeasibility StudiesImmunizationnanoparticlesGoldVaccine
researchProduct

Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery

2020

Extracellular vesicles (EVs) have been showcased as auspicious candidates for delivering therapeutic cargo, including oncolytic viruses for cancer treatment. Delivery of oncolytic viruses in EVs could provide considerable advantages, hiding the viruses from the immune system and providing alternative entry pathways into cancer cells. Here we describe the formation and viral cargo of EVs secreted by cancer cells infected with an oncolytic adenovirus (IEVs, infected cell-derived EVs) as a function of time after infection. IEVs were secreted already before the lytic release of virions and their structure resembled normally secreted EVs, suggesting that they were not just apoptotic fragments of…

MECHANISM0301 basic medicineOncolytic adenovirusHistologyadenoviruHEPATITIS-B-VIRUSGenetic enhancementvirusesTETRASPANINGene deliveryBiologysolukalvotGENE DELIVERYPATHWAY03 medical and health sciences0302 clinical medicineImmune systemlcsh:QH573-671MICROVESICLESEXOSOMESsyöpähoidotlcsh:CytologyMICROPARTICLESadenoviruksetCell BiologyadenovirusExtracellular vesiclesVirologyMicrovesicles3. Good healthOncolytic virus030104 developmental biologyLytic cycle030220 oncology & carcinogenesisCELLSCancer cellonkolyyttiset virukset1182 Biochemistry cell and molecular biologycancer therapyAUTOPHAGYonkolyyttinen virushoitoextracellular vesiclesResearch ArticleDNA delivery
researchProduct